: PARADIGM-HF. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Oct 15, 2014

Overview : The the novel agent LCZ696 (Novartis) that has effects both within and beyond the renin-angiotensin system, was tested against of the ACE inhibitor enalapril, showing fewer HF hospitalizations and mortality from cardiovascular causes, acccording a phase 3 trial PARADIGM-HF. In... more

RELAX TRIAL:”Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Jul 17, 2014

Overview : RELAX-AHF was an international, double-blind, placebo-controlled trial, enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via a central randomisation scheme blocked by study centre to standard care plus 48-h intravenous infusions of placebo or... more

PARAMOUNT: Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction

Jul 17, 2014

Overview : The result showed that levels of NT-proBNP dropped 23% (p=0.005) over 12 weeks but only by 15% (p=0.20) over 36 weeks among those receiving LCZ696 compared with valsartan. LCZ696 was effective for the primary [natriuretic-peptide] end point in every single... more